NasdaqGM - Delayed Quote • USD
Cellectis S.A. (CLLS)
At close: June 7 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 6 | 5 | 6 |
| Avg. Estimate | -0.29 | -0.28 | -0.83 | -0.73 |
| Low Estimate | -0.5 | -0.36 | -1.03 | -1.4 |
| High Estimate | -0.15 | -0.2 | -0.75 | 0.16 |
| Year Ago EPS | -0.58 | -0.19 | -1.77 | -0.83 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 5 | 5 | 4 |
| Avg. Estimate | 4.77M | 3.24M | 16.12M | 100.88M |
| Low Estimate | 1.99M | 1.5M | 10M | 30M |
| High Estimate | 7.5M | 7.5M | 29M | 150.32M |
| Year Ago Sales | 3.56M | 2M | 9.19M | 16.12M |
| Sales Growth (year/est) | 34.00% | 61.90% | 75.40% | 525.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.45 | -0.42 | -0.22 |
| EPS Actual | -0.58 | -0.19 | -0.31 | -0.7 |
| Difference | -0.1 | 0.26 | 0.11 | -0.48 |
| Surprise % | -20.80% | 57.80% | 26.20% | -218.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.29 | -0.28 | -0.83 | -0.73 |
| 7 Days Ago | -0.29 | -0.31 | -1.03 | -1.01 |
| 30 Days Ago | -0.33 | -0.33 | -1.19 | -1.1 |
| 60 Days Ago | -0.31 | -0.31 | -1.12 | -0.83 |
| 90 Days Ago | -0.31 | -0.31 | -1.12 | -0.83 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 1 |
| Up Last 30 Days | 2 | 2 | 4 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | 1 |
Growth Estimates
| CURRENCY IN USD | CLLS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 50.00% | -- | -- | 9.10% |
| Next Qtr. | -47.40% | -- | -- | 11.50% |
| Current Year | 53.10% | -- | -- | 5.70% |
| Next Year | 12.00% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/31/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 11/1/2023 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/8/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 8/7/2023 |
| Maintains | Citigroup: Buy | 4/5/2023 |
| Maintains | Oppenheimer: Outperform | 3/13/2023 |
Related Tickers
ALLO Allogene Therapeutics, Inc.
2.3200
-3.73%
SNSE Sensei Biotherapeutics, Inc.
0.6503
-1.84%
NBTX Nanobiotix S.A.
5.70
-8.06%
CELU Celularity Inc.
3.2500
+0.31%
VYGR Voyager Therapeutics, Inc.
8.42
-0.71%
AVRO AVROBIO, Inc.
1.5200
+4.11%
ALXO ALX Oncology Holdings Inc.
9.01
-2.91%
VALN Valneva SE
8.38
+1.37%
GANX Gain Therapeutics, Inc.
2.2000
-5.98%
KPTI Karyopharm Therapeutics Inc.
0.9602
-1.31%